Get Ready to Cure Your Curiosity: CureVac’s Financial Results and Exciting Business Update for Q3 and the First Nine Months of 2024!
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter A New Chapter for CureVac It’s been an exciting and transformative quarter for CureVac, with significant developments that promise to shape the future of the company. The €400 million upfront payment from the restructured GSK collaboration has been a game-changer, reflecting in our financials and…